Endocrine Society: Thyroid Eye Disease Patients Report Maintained Improvement 2 Years After Teprotumumab Infusions
June 04, 2024
June 04, 2024
BOSTON, Massachusetts, June 4 (TNSres) -- The Endocrine Society issued the following news release:
Most patients with thyroid eye disease treated with teprotumumab didn't require additional treatments nearly 2 years later, according to industry-supported research being presented Sunday at ENDO 2024, the Endocrine Society's annual meeting in Boston, Mass., and published in the journal Thyroid.
"Thyroid eye disease is a lifelong autoimmune disease that can worsen or . . .
Most patients with thyroid eye disease treated with teprotumumab didn't require additional treatments nearly 2 years later, according to industry-supported research being presented Sunday at ENDO 2024, the Endocrine Society's annual meeting in Boston, Mass., and published in the journal Thyroid.
"Thyroid eye disease is a lifelong autoimmune disease that can worsen or . . .